Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.
Vaccine
; 37(31): 4243-4245, 2019 07 18.
Article
em En
| MEDLINE
| ID: mdl-31239214
In the Saguenay-Lac-Saint-Jean region of Quebec, 83% of the populationâ¯≤20â¯years (nâ¯â
â¯59,500) was immunized in 2014 with the four-component Serogroup B meningococcal vaccine to control a long-lasting outbreak caused by a virulent ST-269 Serogroup B Neisseria meningitidis clone. Following the campaign, invasive meningococcal B disease (B-IMD) incidence fell sharply in the target population from 11.4/100,000 in 2006-2014 to 0.4/100,000 in 2014-2018 (pâ¯<â¯0.0001). Five B-IMD cases occurred in the region from July 2014 to June 2018, including one vaccinated child, one unvaccinated young adult and 3 unvaccinated elderly adults. Estimate of direct vaccine protection was 79% [95%CI:-231%;99%]. The overall campaign impact in the region taking into account the decrease in B-IMD incidence at provincial level was a 86% [95%CI:-2%;98%] decrease in B-IMD risk. The campaign impact was mostly seen in the target age-group suggesting no herd effect among unvaccinated older adults.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Vacinação
/
Programas de Imunização
/
Neisseria meningitidis Sorogrupo B
/
Meningite Meningocócica
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2019
Tipo de documento:
Article